Cadrenal Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Cadrenal Therapeutics, Inc. (CVKD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$13.24 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-31
- Cadrenal Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$13.24M.
- Cadrenal Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$10.65M.
- Cadrenal Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$8.36M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 11 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$13.24M 10-K · filed 2026-03-31 | ||
| 2024-12-31 | -$10.65M 10-K · filed 2026-03-31 | $10.65M 10-K · filed 2025-03-13 | |
| 2023-12-31 | -$8.36M 10-K · filed 2025-03-13 | ||
| 2022-12-31 | -$6.71M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |